Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes...
Company Statement: Emergent BioSolutions Statement on Status of Current Manufacturing of COVID-19 Vaccine at Company’s Baltimore Bayview Facility
At Emergent (NYSE: EBS), safety and quality are our top priorities. Our Bayview facility has been designed and validated to meet all current Good Manufacturing...
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor...
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020. The Company also reaffirmed its full year 2021...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020,...
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized...
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services...
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for...
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of...
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent’s COVID-19 Human Hyperimmune Globulin (COVID-HIG) product...
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and nine months ended September 30, 2020 and updated its full year 2020...
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2020, recent...